2 results match your criteria: "Sahlgrenska Cancer Center at University of Gothenburg[Affiliation]"
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.
Nat Commun
September 2017
From the Sahlgrenska Translational Melanoma Group, Institute of Clinical Science, Departments of Surgery and Oncology, Sahlgrenska Cancer Center at University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, 405 30, Sweden.
Immune checkpoint inhibitors and adoptive cell transfer (ACT) of autologous tumor-infiltrating T cells have shown durable responses in patients with melanoma. To study ACT and immunotherapies in a humanized model, we have developed PDXv2.0 - a melanoma PDX model where tumor cells and tumor-infiltrating T cells from the same patient are transplanted sequentially in non-obese diabetic/severe combined immune-deficient/common gamma chain (NOG/NSG) knockout mouse.
View Article and Find Full Text PDFCancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins.
Cancer Res
April 2016
Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Cancer Center at University of Gothenburg, Gothenburg, Sweden.
Article Synopsis
- HMBA, a compound used over 25 years ago in cancer treatment, is revealed to specifically inhibit bromodomains, crucial proteins that influence gene expression.* -
- The study demonstrates that HMBA can induce differentiation in certain cancer cells and shows potential for triggering cell-cycle arrest and apoptosis in Myc-driven B-cell lymphoma.* -
- This research highlights HMBA's anticancer effects in mouse models and suggests its relevance in current clinical trials involving BET inhibitors, which may help in identifying patient responses and treatment strategies.*